Shopping Cart
- Remove All
Your shopping cart is currently empty
Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $214 | 35 days | |
| 5 mg | $540 | 35 days |
| Description | Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface. |
| Targets&IC50 | PPARγ LBD:(ki)1.2 μM, PPARγ LBD Leriglitazone: 680 nM(EC) |
| Synonyms | Hydroxypioglitazone |
| Molecular Weight | 372.44 |
| Formula | C19H20N2O4S |
| Cas No. | 146062-44-4 |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.